Please try another search
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. Its lead product is Sevuparin, a lipopolysaccharide to treat patients with sepsis, septic shock, and other systemic inflammation conditions, which is under Phase Ib clinical study. The company was founded in 2011 and is headquartered in Stockholm, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Torsten Goesch | 63 | 2014 | Independent Director |
Lennart Lindbom | - | 2021 | Scientific Advisor |
Eddie Weitzberg | 67 | 2021 | Scientific Advisor |
Ellen K. Donnelly | 48 | 2020 | Independent Director |
Viktor Drvota | 57 | 2016 | Chairman of the Board |
Mats Wahlgren | - | 2021 | Scientific Advisor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review